<DOC>
	<DOCNO>NCT01908621</DOCNO>
	<brief_summary>The purpose study compare safety efficacy stem cell mobilization use G-CSF ( filgrastim ) alone vs. intermediate-dose cytosine arabinoside plus G-CSF multiple myeloma patient .</brief_summary>
	<brief_title>Randomized Trial G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization Multiple Myeloma Patients .</brief_title>
	<detailed_description>Autologous hematopoietic stem cell transplantation ( autoHSCT ) standard treatment eligible patient suffer multiple myeloma ( MM ) . Tandem autoHSCT allow improve result therapy . Nowadays , 99 % procedure perform use peripheral blood source stem cell . Hence , crucial point harvest adequate number stem cell allow hematopoietic recovery . The number 5 Ã— 10^6 CD34+ cells/kg consider optimal level , far double autoHSCT concern . There two main mobilization strategy use : base G-CSF alone combination chemotherapy ( cyclophosphamide ( CY ) dose range 1.5-7 g/m2 mainly use MM set ) . However , proportion patient ( 5-40 % ) fail collect minimum number cell require . Novel agent , like plerixafor , CXCR4 inhibitor , may enable effective CD34+ cell harvest `` poor mobilizers '' . Nevertheless , optimal first-line cost-effective protocol mobilization hematopoietic stem cell determine far . Randomized trial compare chemomobilization use CY + G-CSF G-CSF alone , conduct far , demonstrate clear advantage addition CY growth factor . Intermediate-dose cytosine arabinoside ( AraC ) , 1.6 g/m2 plus filgrastim , show produce high efficacy first second-line mobilization regimen patient lymphoid malignancy , include MM . In retrospective comparison , strategy significantly effective CY + filgrastim . This suggest type chemotherapy agent add G-CSF may play role mobilization efficacy combination AraC G-CSF may effective G-CSF use alone . The goal current study verify hypothesis randomize control trial .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Multiple myeloma patient consider eligible tandem autologous stm cell transplantation procedure . 2 . Must receive least one line therapy include six cycle contain component like thalidomide , bortezomib , lenalidomide melphalan . 3 . Must achieve partial remission ( PR ) good response assess International Myeloma Working Group guideline . 4 . Must 1865 year age . 5 . Must World Health Organization performance status 01 . 6 . Time form discontinuation administration chemotherapy agent must least four week immunomodulatory drug least seven day . 7 . Hemoglobin level &gt; 8 g/dl , Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L , Platelet count &gt; 100 x 109/L . 8 . Serum creatinine &lt; 1.5 x upper limit normal ( ULN ) , serum bilirubin &lt; 1.5 ULN , serum aspartate transaminase ( AST/SGOT ) &lt; 2.5 x ULN , serum alanine transaminase ( ALT/SGPT ) &lt; 2.5 x ULN . 9 . Negative human immunodeficiency virus ( HIV ) infection test . 10 . Negative pregnancy test . 11 . Must understand voluntarily sign informed consent form . 1 . Failure prior , firstline mobilization regimen . 2 . Bone marrow plasma cell infiltration 20 % . 3 . Administration growthfactor GCSF within 4 week start study treatment . 4 . Administration GCSF within 14 day start study treatment . 5 . Ongoing active infection . 6 . Coexisting neoplasm , multiple myeloma . 7 . Pregnant lactating female . 8 . Patients treat use autologous allogenic stem cell transplantation past . 9 . Positive human immunodeficiency virus ( HIV ) infection test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>mobilization</keyword>
	<keyword>G-CSF</keyword>
	<keyword>filgrastim</keyword>
	<keyword>cytosine arabinoside</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>